Form 8-K - Current report:
SEC Accession No. 0001140361-25-040675
Filing Date
2025-11-06
Accepted
2025-11-06 08:25:36
Documents
14
Period of Report
2025-11-06
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20058362x4_8k.htm   iXBRL 8-K 34838
2 EXHIBIT 99.1 ny20058362x4_ex99-1.htm EX-99.1 12616
3 EXHIBIT 99.2 ny20058362x4_ex99-2.htm EX-99.2 20567
  Complete submission text file 0001140361-25-040675.txt   211761

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ird-20251106.xsd EX-101.SCH 3860
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20251106_lab.xml EX-101.LAB 21967
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20251106_pre.xml EX-101.PRE 16042
17 EXTRACTED XBRL INSTANCE DOCUMENT ny20058362x4_8k_htm.xml XML 4216
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 251456328
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)